Humana Inc. Files 8-K for Regulation FD Disclosure

TL;DR

Humana dropped an 8-K, likely a Reg FD update. Watch for details.

AI Summary

Humana Inc. filed a Form 8-K on March 3, 2025, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of the disclosure, dollar amounts, or other specific events beyond its classification as a Regulation FD disclosure.

Why It Matters

This filing indicates Humana Inc. is making a public disclosure under Regulation FD, which could contain material information relevant to investors.

Risk Assessment

Risk Level: medium — The filing is a standard 8-K for a Regulation FD disclosure, which can sometimes precede significant news, but lacks specific details to assess immediate risk.

Key Players & Entities

• HUMANA INC (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• 500 West Main Street, Louisville, Kentucky 40202 (address) — Principal executive offices
• March 3, 2025 (date) — Date of report

FAQ

From the Filing

0000049071-25-000009.txt : 20250303 0000049071-25-000009.hdr.sgml : 20250303 20250303073010 ACCESSION NUMBER: 0000049071-25-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250303 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20250303 DATE AS OF CHANGE: 20250303 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANA INC CENTRAL INDEX KEY: 0000049071 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 610647538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05975 FILM NUMBER: 25693786 BUSINESS ADDRESS: STREET 1: 500 W MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 5025801000 MAIL ADDRESS: STREET 1: 500 W. MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 FORMER COMPANY: FORMER CONFORMED NAME: EXTENDICARE INC DATE OF NAME CHANGE: 19740404 FORMER COMPANY: FORMER CONFORMED NAME: HERITAGE HOUSE OF AMERICA INC DATE OF NAME CHANGE: 19671129 8-K 1 hum-20250303.htm 8-K hum-20250303 0000049071 false 0000049071 2025-03-03 2025-03-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 ( March 3, 2025 ) Humana Inc. (Exact name of registrant as specified in its charter) Delaware 001-5975 61-0647538 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 500 West Main Street , Louisville , Kentucky 40202 (Address of principal executive offices, including zip code) ( 502 ) 580-1000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock HUM New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ Item 7.01 Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between March 3, 2025 and March 31, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $15.88 in diluted earnings per common share (“EPS”) or approximately $16.25 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This guidance is consistent with the guidance issued in Humana’s press release dated February 11, 2025. The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accou